[go: up one dir, main page]

WO2001022980A1 - Traitement des effets secondaires - Google Patents

Traitement des effets secondaires Download PDF

Info

Publication number
WO2001022980A1
WO2001022980A1 PCT/AU2000/001159 AU0001159W WO0122980A1 WO 2001022980 A1 WO2001022980 A1 WO 2001022980A1 AU 0001159 W AU0001159 W AU 0001159W WO 0122980 A1 WO0122980 A1 WO 0122980A1
Authority
WO
WIPO (PCT)
Prior art keywords
substance
treatment
animal
primary
juice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2000/001159
Other languages
English (en)
Inventor
David Rudov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ3050A external-priority patent/AUPQ305099A0/en
Priority claimed from AUPQ4064A external-priority patent/AUPQ406499A0/en
Application filed by Individual filed Critical Individual
Priority to GB0206401A priority Critical patent/GB2369299A/en
Priority to DE10085032T priority patent/DE10085032T1/de
Priority to AU76334/00A priority patent/AU771206B2/en
Publication of WO2001022980A1 publication Critical patent/WO2001022980A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • This invention relates to processes and products for the treatment of animals
  • the treatment of animals including veterinary treatment of domestic animals, sporting
  • reaction products Such side effects include for example rashes, headaches, nausea,
  • Antibiotics are frequently prescribed and used in the treatment of animals, including
  • CFS chronic fatigue syndrome
  • antibiotics to animals, including human patients, both before, during and after surgery or other interventions including intrusive examinations is common. Such administration of antibiotics is carried out to avoid or reduce trauma that may be
  • respiratory infections including obstructive pulmonary infections
  • a method of treating an animal including a human, e.g. for a pathological or injured or abnormal condition or for
  • the method including a primary
  • the primary treatment substance being selected from the group of treatment substances for animals
  • antibiotics and other pharmacologically effective substances for treating animals including antibiotics and other pharmacologically effective substances for treating animals, the administration of such primary substance being commonly or occasionally associated with undesirable side effects being experienced by the animal, the method of treating further comprising administering to the animal, in conjunction with the administration of the
  • substance including an extract from cereal plants, the extract comprising a pharmaceutically
  • the secondary substance used in the present invention comprises a
  • substance or material including pharmaceuticals, herbal or naturopathic substances, and
  • the product for the adjunct treatment of animals, including humans, the product comprising a
  • the process including the steps of administering an effective quantity of a substance of the kind described to the animal in a manner and over a period of time to reduce the incidence
  • the product comprising a substance of the kind described provided in a concentration and medium for administration
  • secondary treatment substance occurs simultaneously with, and may also be continued after,
  • Extracts from barley and wheat are also believed to be effective.
  • the wheat may comprise Triticum vulgare or aestivum, T. durum, T. compactum. or triticale. Corn, rice,
  • oats maize, sorghum and millet may also be effective.
  • the extract is derived from the green leafy part of the plant, or at least
  • the leaves of the plant are preferably treated to yield the extract before the plant
  • the extraction is preferably carried out by squeezing, crushing and/or grinding
  • the extract from the cereal plants comprises substantially only the water
  • the plant extract may be used in the concentration in which it is derived from the
  • the extract may be concentrated and some or substantially
  • the extracted plant may be removed.
  • the extracted plant may be removed.
  • the matter may be dried, such as by spray drying to yield a powder for mixing with the carrier.
  • the spray drying is preferably carried out at a temperature of about 50°C and preferably
  • Other possible stabilisation processes for the juice include partial concentration of the derived juice to provide a concentrated liquid, freeze drying of the derived juice, and
  • the stabilisation or mixing with the carrier or both is carried out within a
  • the extract may be produced by firstly drying plant matter after which the dried material is comminuted to yield a powder which includes ingredients
  • the carrier for the extract may be any suitable material such as a liquid (e.g. water or other solvent), cream, lotion, oil, gel or powder.
  • a liquid e.g. water or other solvent
  • cream, lotion, oil, gel or powder e.g. water or other solvent
  • the carrier may comprise a
  • a water based or aqueous carrier capable of carrying water soluble ingredients to
  • Benzyl alcohol is a suitable carrier component for Benzyl alcohol
  • transdermal take up of the active ingredients.
  • the carrier for the extract may comprise the same carrier as used for the primary
  • antibiotics can be administered to an animal in a lotion or
  • the substance of the kind described can be mixed with the primary treatment substance in the same carrier for
  • compositions and concentrations the substance of the kind described can be mixed with the intravenous solution for simultaneous administration.
  • the primary treatment substance and secondary treatment substance can be administered
  • the carrier includes an anti-microbial agent so as to kill or at least inhibit
  • anti-microbial agent is an anti -bacterial agent.
  • the agent may
  • the anti-microbial agent may be added to the substance during production or may be present in the carrier if the carrier for example is a
  • the anti-microbial agent is preferably active to
  • the extract is substantially
  • the plants from which the extract is derived may be
  • micro-organisms at that stage.
  • the subsequent harvesting and processing may also be
  • the ratio of the extract to the carrier may be anywhere within a large range of
  • the ratio of base carrier to plant extract (and other additives if provided) may be anywhere between 1 to 5 and 200 to 1 (by weight).
  • the substance has a generally neutral pH in the range 6.0 to 8.0.
  • the pH may be in the range 6.5 to 7.5.
  • a particularly preferred method of transdermal uptake is by applying the
  • the mouth for uptake through mucous tissues of the mouth.
  • the substance to the mouth for uptake through mucous tissues of the mouth.
  • the mouth for uptake through mucous tissues of the mouth.
  • substance may be administered sublingually, e.g. in the form of drops of the substance taken
  • a suitable route of administration is effective for uptake of the substance into the body.
  • chronic fatigue syndrome patients and in race horses indicate applicability of the present invention as an adjunct treatment for an animal, including a human, being treated for a
  • precautionary or preventative treatment e.g. before, during or after a traumatic event or

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une nouvelle utilisation d'une substance contenant un extrait liquide de jus de céréales (comprenant des herbages naturels) acceptable sur le plan pharmaceutique et contenu dans un support ou excipient acceptable sur le plan pharmaceutique, cette substance étant destinée à être appliquée ou absorbée par un animal. Cette substance est utilisée pour fabriquer un produit de traitement annexe d'animaux et d'humains destiné à réduire l'incidence ou la gravité des effets secondaires associés au traitement chimique primaire qui leur est administré. En outre, cette invention concerne un produit destiné au traitement annexe d'animaux, un procédé de traitement annexe d'animaux, un produit de traitement secondaire annexe qui réduit efficacement l'incidence ou la gravité des effets secondaires, ainsi qu'un procédé d'amélioration du traitement thérapeutique d'un animal.
PCT/AU2000/001159 1999-09-24 2000-09-25 Traitement des effets secondaires Ceased WO2001022980A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB0206401A GB2369299A (en) 1999-09-24 2000-09-25 Side effects treatment
DE10085032T DE10085032T1 (de) 1999-09-24 2000-09-25 Behandlung von Nebenwirkungen
AU76334/00A AU771206B2 (en) 1999-09-24 2000-09-25 Side effects treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPQ3050 1999-09-24
AUPQ3050A AUPQ305099A0 (en) 1999-09-24 1999-09-24 Side effects treatment
AUPQ4064A AUPQ406499A0 (en) 1999-11-16 1999-11-16 Side effects treatment
AUPQ4064 1999-11-16

Publications (1)

Publication Number Publication Date
WO2001022980A1 true WO2001022980A1 (fr) 2001-04-05

Family

ID=25646155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2000/001159 Ceased WO2001022980A1 (fr) 1999-09-24 2000-09-25 Traitement des effets secondaires

Country Status (3)

Country Link
DE (1) DE10085032T1 (fr)
GB (1) GB2369299A (fr)
WO (1) WO2001022980A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015804A1 (fr) * 2001-08-17 2003-02-27 David Rudov Traitement permettant d'ameliorer le fonctionnement du systeme nerveux central

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787591A (en) * 1971-09-16 1974-01-22 Japan Natural Food Co Ltd Process for producing powders of green leaves of wheat and barley
AU8198587A (en) * 1986-12-03 1988-06-09 David Rudov Pharmacological/cosmetic preparation for external application containing cereal plant extract
WO1991011191A1 (fr) * 1990-02-05 1991-08-08 David Rudov Compositions pharmacologiques contenant des extraits derives de la famille des graminacees et leurs utilisations
EP0620007A1 (fr) * 1993-02-16 1994-10-19 SOKEN Co., Ltd. Agent contre les ulcéres
CN1098851A (zh) * 1993-08-16 1995-02-22 青岛太平洋科技实业公司 海藻顺通面条
WO1995006459A1 (fr) * 1993-09-01 1995-03-09 Helsinki University Licensing Ltd. Composition stable contenant du jus de germe de ble et procede de production
CN1106227A (zh) * 1994-09-02 1995-08-09 沈阳振兴食品厂 食用菌挂面及其制备方法
JP2000044459A (ja) * 1998-07-29 2000-02-15 Tekunooburu:Kk 皮膚外用剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787591A (en) * 1971-09-16 1974-01-22 Japan Natural Food Co Ltd Process for producing powders of green leaves of wheat and barley
AU8198587A (en) * 1986-12-03 1988-06-09 David Rudov Pharmacological/cosmetic preparation for external application containing cereal plant extract
WO1991011191A1 (fr) * 1990-02-05 1991-08-08 David Rudov Compositions pharmacologiques contenant des extraits derives de la famille des graminacees et leurs utilisations
EP0620007A1 (fr) * 1993-02-16 1994-10-19 SOKEN Co., Ltd. Agent contre les ulcéres
CN1098851A (zh) * 1993-08-16 1995-02-22 青岛太平洋科技实业公司 海藻顺通面条
WO1995006459A1 (fr) * 1993-09-01 1995-03-09 Helsinki University Licensing Ltd. Composition stable contenant du jus de germe de ble et procede de production
CN1106227A (zh) * 1994-09-02 1995-08-09 沈阳振兴食品厂 食用菌挂面及其制备方法
JP2000044459A (ja) * 1998-07-29 2000-02-15 Tekunooburu:Kk 皮膚外用剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BHATTACHARYA ET AL., SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 33, 1998, pages 159 - 163 *
HIDVEGI ET AL., CANCER BIOTHERAPY AND RADIO PHARMACEUTICALS, vol. 14, no. 4, 1999, pages 277 - 289 *
PATENT ABSTRACTS OF JAPAN *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015804A1 (fr) * 2001-08-17 2003-02-27 David Rudov Traitement permettant d'ameliorer le fonctionnement du systeme nerveux central

Also Published As

Publication number Publication date
GB0206401D0 (en) 2002-05-01
GB2369299A (en) 2002-05-29
DE10085032T1 (de) 2002-10-10

Similar Documents

Publication Publication Date Title
US5391372A (en) Methods of treating colic and founder in horses
EP2155222B1 (fr) Extrait de trigonella foenum-graecum
DE69909794T2 (de) Verwendung eines dipeptids für wiederherstellungsprozesse
US7198806B2 (en) Composition and method for treatment and prevention of pruritis
EP0279984B1 (fr) Utilisation pharmaceutique des extraits de graminées
RU2095060C1 (ru) Композиция, обладающая аналгетической или противовоспалительной активностью, способ аналгезии или лечения аллергических заболеваний
RU2132197C1 (ru) Средство, обладающее противоопухолевым и иммуномодулирующим действием ("олексин")
KR100699790B1 (ko) 댕댕이나무 추출물을 포함하는 간 질환 예방 및 치료효과를 가지는 약제학적 조성물
AU771206B2 (en) Side effects treatment
EP4464328A1 (fr) Composition pharmaceutique pour traiter ou améliorer l'oedème et la stase sanguine après une chirurgie ouverte
US20060240120A1 (en) Composition for lowering blood glucose
JP6590233B1 (ja) 皮膚疾患治療剤及びその製造方法
WO2001022980A1 (fr) Traitement des effets secondaires
US9364510B2 (en) Botanical composition and methods of manufacture and use
EP2680924B1 (fr) Nouvelle composition à base d'herbes utilisée pour traiter un calcul rénal et d'autres troubles des voies urinaires
RU2019180C1 (ru) Средство для лечения подкожной фибросаркомы и способ его получения
AU599725B2 (en) Pharmacological/cosmetic preparation for external application containing cereal plant extract
WO2000064461A1 (fr) Traitement permettant d'ameliorer la fonction respiratoire
Joyce Thymol therapy in actinomycosis
CN115813957B (zh) 海蒿子多酚在制备治疗阿尔兹海默病药物中的应用
CN118593461B (zh) 一种组合物、药物及其制备、检测、定位方法和用途
WO1991011191A1 (fr) Compositions pharmacologiques contenant des extraits derives de la famille des graminacees et leurs utilisations
RU2122418C1 (ru) Средство для лечения хронического гепатита неинфекционной этиологии
US20180036361A1 (en) Compositions and methods for treatment of pain
CN100450505C (zh) 一种治疗脚气病的中药脚气膏

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 200206401

Country of ref document: GB

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 76334/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10088954

Country of ref document: US

RET De translation (de og part 6b)

Ref document number: 10085032

Country of ref document: DE

Date of ref document: 20021010

WWE Wipo information: entry into national phase

Ref document number: 10085032

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 76334/00

Country of ref document: AU